ENDRA Life Sciences
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -39 | -39 | -39 |
EBITDA | -1,271 | -3,129 | -1,556 |
EBIT | -1,311 | -3,169 | -1,595 |
Net Income | -1,311 | -3,169 | -1,595 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -1,119 | -4,611 | -1,164 |
Cash | 356 | 762 | 794 |
Basic Shares | 1,199 | 787 | 761 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -206 | -275 | -234 | |
EBITDA | -6,870 | -11,301 | -9,784 | -12,923 |
EBIT | -7,027 | -11,507 | -10,060 | -13,157 |
Net Income | -7,027 | -11,507 | -10,060 | -13,179 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -5,199 | -7,416 | -9,582 | -12,971 |
Cash | 762 | 3,229 | 2,833 | 4,889 |
Basic Shares | 787 | 1,122 | 1,707 | 1,930 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.63 |
2026-03-31 | -$1.09 |
2025-12-31 | -$2.23 |
2025-09-30 | -$2.10 |